WE STRIVE TO PREVENT AND CURE DEMENTIA

For decades, Eisai has led the way in dementia research and development. Now we’re broadening our scope, taking a multi-dimensional, targeted path to our ultimate goal: prevention and a cure. Here’s a quick look at what we’re working on right now.



A BLOOD TEST FOR ALZHEIMER’S?

A BLOOD TEST FOR ALZHEIMER’S?

We’re collaborating with Sysmex on a potential blood-based test for predicting amyloid pathology. This automated immune-assay system under investigation could also be utilized as a simpler and more cost-effective method to identify participants for clinical trials exploring a variety of AD therapies now in development.




Learn from leading AD experts about the A/T/N system and how it may shape clinical practice and therapy development

Discover the A/T/N system – a biomarker-based classification system that classifies individuals using core AD pathophysiological features: amyloid-β(A), tau (T) and neurodegeneration (N). Presented at the 2020 Alzheimer’s Association International Conference (AAIC), the three presentations provide a state-of-the-art overview on the validation and qualification of the A/T/N system and its evolution to A/T/N/x for AD clinical practice and therapy development.

“The A/T/N system offers a framework to define Alzheimer’s disease in a continuum using biologically rooted measurements. It circumvents the limitations of the traditional, clinical phenotype-based approach, and has the potential to facilitate therapeutic interventions at the early stages of the disease.”

Harald Hampel
Chief Medical Officer
Neurology Business Group